Petal study: safety, tolerability and effectiveness of elagolix, an oral GnRH antagonist for endometriosis
OA: closed
CC0
⤵ 6 in-corpus citations
AI-generated summary
This petal study evaluated the safety, tolerability, and effectiveness of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, in patients with endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (6)
- Gonadotropin-releasing hormone analogues for endometriosis 2023
- Entwicklung oraler nichtpeptidischer GnRH-Antagonisten 2020
- Overview of elagolix for the treatment of endometriosis 2016
- Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain 2015
- Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density 2014
- Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study 2013
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-09-17T06:32:46.214484+00:00
License: CC0
· commercial use OK